SCM
LAB icon

Stevens Capital Management’s Standard BioTools LAB Stock Holding History

Stevens Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-12,894
Closed -$316K – 1122
2014
Q3 		$316K Buy
+12,894
New +$363K 0.01% 721

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stevens Capital Management's LAB Position: Q4 2014 in Review

Stevens Capital Management sold out of Standard BioTools (LAB) in Q4 2014, closing a stake of 12,894 shares — an estimated $316K sold.

Stevens Capital Management first reported a position in LAB in Q3 2014 and held it in 1 quarter. The position peaked at $316K in Q3 2014. 100 funds tracked by Wall St. Rank hold LAB as of Q4 2014.

  • Stevens Capital Management reported no remaining Standard BioTools position as of Q4 2014 after selling out during the quarter.
  • Stevens Capital Management sold 12,894 Standard BioTools shares in Q4 2014, an estimated $316K.
  • Stevens Capital Management first reported a position in Standard BioTools in Q3 2014 and held it in 1 quarter.
  • Stevens Capital Management's Standard BioTools position peaked at $316K in Q3 2014.
  • 100 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2014.

Based on Stevens Capital Management's 13F filing for Q4 2014, filed 10 Feb 2015.